Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2024 · third_quarter · Q3
Issues related to supply chain; issues related to RSV; issues related to Type 1 Diabetes; issues related to Pharmacy Benefit Managers (PBMs); issues related to Vaccines; issues related to Taxes; and issues related to over-the-counter.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Source: Senate LDA
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Protecting Patients Against PBM Abuses Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Protecting Patients Against PBM Abuses Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Protecting Patients Against PBM Abuses Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Living Donor Protection Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Preparing for All Hazards and Pathogens Reauthorization Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Protecting Americans’ Investments from Woke Policies Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Protecting Americans’ Investments from Woke Policies Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Protecting Americans’ Investments from Woke Policies Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Lower Costs, More Transparency Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Lower Costs, More Transparency Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Prevent Illegal Gun Resales Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Prevent Illegal Gun Resales Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Prevent Illegal Gun Resales Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
SCREEN for Type 1 Diabetes Act of 2024
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
SCREEN for Type 1 Diabetes Act of 2024
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Pharmacy Benefit Manager Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Pharmacy Benefit Manager Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Pharmacy Benefit Manager Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
SCREEN for Type 1 Diabetes Act of 2024
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
SCREEN for Type 1 Diabetes Act of 2024
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to supply chain; and issues related to TRIP Waivers.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to supply chain; and issues related to TRIP Waivers.
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Prescription Information Modernization Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance; and general issues related to Pandemic Preparedness.
Protecting Patients Against PBM Abuses Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Protecting Patients Against PBM Abuses Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Protecting Patients Against PBM Abuses Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Living Donor Protection Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Drug Shortage Prevention Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Fairness for Patient Medications Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Fairness for Patient Medications Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
To release the reversionary interest of the United States in certain non-Federal land in Salt Lake City, Utah, and for other purposes.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Wild Horse and Burro Protection Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Wild Horse and Burro Protection Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Wild Horse and Burro Protection Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance; and general issues related to Pandemic Preparedness.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Modern Authentication of Pharmaceuticals Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Share the Savings with Seniors Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance; and general issues related to Pandemic Preparedness.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance; and general issues related to Pandemic Preparedness.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Pharmacy Benefit Manager Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Pharmacy Benefit Manager Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Pharmacy Benefit Manager Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Affordable Prescriptions for Patients Act of 2023
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.150 "Affordable Prescriptions for Patients Act of 2023".
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 "Vaccine Access Improvement Act"; and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to VICP; and issues related to HR 3656 "Vaccine Access Improvement Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to March-In; and issues related to supply chain.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to VICP; and issues related to HR 3656 "Vaccine Access Improvement Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 "Vaccine Access Improvement Act"; and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to March-In; and issues related to supply chain.
Lower Costs, More Cures Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to funding for Pandemic influenza funding; issues related to RX to OTC switch; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; general issues related to HR 5376 "Build Back Better Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to COVID Vaccine Development; issues related to Clinical Trial Diversity; issues related to HR 19 "Lower Costs, More Cures Act of 2021; issues related to Accelerated Approval; issues related to HR 5416 "Give Kids a Chance Act"; issues related to HR 6972 "Give Kids a Chance Act of 2022"; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; and general issues related to Insulin pricing.
Reproductive Rights are Human Rights Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to HR 6972 "Give Kids a Chance Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to "Improving Needed Safeguards for Users for Lifesaving Insulin Now (INSULIN) Act"; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; and issues related to HR 3576 "Inflation Reduction Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to taxes; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; issues related to tax credits; issues related to Vaccine Injury Compensation Program; issues related to Vaccine in Children Program; and issues related to HR 3656 "Vaccine Access Improvement Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness in PREVENT Pandemics ACT; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to S.3700 "Affordable Insulin Now Act"; issues related to S.2199 "Insulin Price Reduction Act"; issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; issues related to HR 5376 "Inflation Reduction Act"; issues related to drug pricing in Inflation Reduction Act; issues related to cosmetics reform in the Modernization of Cosmetics Regulations Act; issues related to Copay Accumulators; issues related to Vaccine in Children Program; issues related to Q1/Q2 budget spend; issues related to ACNU "additional condition for prescription use; and issues related to HR 3656 "Vaccine Access Improvement Act".
Vaccine Access Improvement Act of 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to H.R. 3656 "Vaccine Access Improvement Act of 2021"; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; and issues related to HR 5376 Build Back Better Act.
Inflation Reduction Act of 2022
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to funding for Pandemic influenza funding; issues related to RX to OTC switch; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; general issues related to HR 5376 "Build Back Better Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to COVID Vaccine Development; issues related to Clinical Trial Diversity; issues related to HR 19 "Lower Costs, More Cures Act of 2021; issues related to Accelerated Approval; issues related to HR 5416 "Give Kids a Chance Act"; issues related to HR 6972 "Give Kids a Chance Act of 2022"; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; and general issues related to Insulin pricing.
Inflation Reduction Act of 2022
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness in PREVENT Pandemics ACT; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to S.3700 "Affordable Insulin Now Act"; issues related to S.2199 "Insulin Price Reduction Act"; issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; issues related to HR 5376 "Inflation Reduction Act"; issues related to drug pricing in Inflation Reduction Act; issues related to cosmetics reform in the Modernization of Cosmetics Regulations Act; issues related to Copay Accumulators; issues related to Vaccine in Children Program; issues related to Q1/Q2 budget spend; issues related to ACNU "additional condition for prescription use; and issues related to HR 3656 "Vaccine Access Improvement Act".
Inflation Reduction Act of 2022
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; issues related to HR 5376 Build Back Better Act; issues related to tax credits; and issues related to S.4417 "Patent Trial and Appeal Board Act of 2022".
Issues related to Medicare Negotiations; issues related to 340B; and issues related to Medicaid Drug Rebate Program rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2024 · second_quarter · Q2
Issues related to Medicare Negotiations; issues related to 340B; and issues related to Medicaid Drug Rebate Program rule.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related HR 5339 and S. 3131 "Orphan Cures Act"; Rare Pediatric Priority Review Voucher Program related to HR 7834 "Creating Hope Reauthorization Act of 2024"; Orphan Drug Negotiation within HR5378 "Inflation Reduction Act"; issues related to drug price negotiations; issues related to COPD Research funding; Biologic/Small Molecule drug negotiation eligibility within HR7174 "EPIC Act"; CDC Type 1 Diabetes Awareness and Education with LHHS appropriations; issues related to HR 8698 and S.4504 "SCREEN for Type 1 Diabetes"; issues related to HRSA - Type 1 Diabetes Screening; general issues related to Inflation Reduction Act; issues related to March-In rights; and issues related to Routine Immunizations Rates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2024 · first_quarter · Q1
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to supply chain; and issues related to TRIP Waivers.
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; issues related to intellectual property; issues related to Transplant; issues related to Seasonal Influenza Vaccines; issues related HR 5339 and S. 3131 "Orphan Cures Act"; issues related to HR 7834 "Creating Hope Reauthorization Act of 2024"; issues related to HR 7174 "EPIC Act"; issues related to Inflation Reduction Act, issues related to drug price negotiations; issues related to COPD Research funding; and issues related to HR 6283 "DRUG Act".
Issues related to Medicare Negotiations; issues related to 340B; and issues related to Medicaid Drug Rebate Program rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2023 · fourth_quarter · Q4
Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related to RSV Immunizations; issues related to routine immunization rates; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR365 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related FDA; issues related to FDA Drug Development; issues related to Pharmacy Benefit Managers (PBMs); issues related to insurance design; issues related to S. 1542 "DRUG Act"; issues related to S. 1375 "HELP Copays Act"; issues related to tax credits; issues related to S. 1339 "PBM Reform Act"; issues related to "INSULIN ACT"; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuse Act"; HR 4421 "Preparing for All Hazards Pathogens Reauthorization Act"; issues related to seasonal influenza vaccines' issues related to HR 2923 "Living Donor Protection Act"; issues related to Type 1 Diabetes screening; issues related to pandemic preparedness; and issues related to intellectual property.
Issues related to Medicare Negotiations; issues related to drug pricing negotiations; issues related to 340B; issues related to Medicaid Drug Rebate Program rule; and issues related to vaccines.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 (117th) Vaccine Access Improvement Act; issues related to March-In; and issues related to supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2023 · third_quarter · Q3
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
Issues related to Medicare Negotiations; issues related to drug pricing negotiations; and issues related to 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2023 · second_quarter · Q2
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); issues related to HR 3656 "Vaccine Access Improvement Act"; and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
Issues related to Medicare Negotiations; issues related to drug pricing negotiations; issues related to 340B; and issues related to Flu reimbursement.
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to supply chain; issues related to transplants; issues related to delinking; and issues related to HR 2880 "Protecting Patients Against PBM Abuses Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2023 · first_quarter · Q1
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance; and general issues related to Pandemic Preparedness.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2022 · fourth_quarter · Q4
General issues related to taxes; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; issues related to tax credits; issues related to Vaccine Injury Compensation Program; issues related to Vaccine in Children Program; and issues related to HR 3656 "Vaccine Access Improvement Act".
Issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness in PREVENT Pandemics ACT; issues related to Reconciliation; issues related to Cosmetic Reform; issues related to S.3700 "Affordable Insulin Now Act"; issues related to S.2199 "Insulin Price Reduction Act"; issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; issues related to HR 5376 "Inflation Reduction Act"; issues related to drug pricing in Inflation Reduction Act; issues related to cosmetics reform in the Modernization of Cosmetics Regulations Act; issues related to Copay Accumulators; issues related to Vaccine in Children Program; issues related to Q1/Q2 budget spend; issues related to ACNU "additional condition for prescription use; and issues related to HR 3656 "Vaccine Access Improvement Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2022 · third_quarter · Q3
Issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to HR 6972 "Give Kids a Chance Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to "Improving Needed Safeguards for Users for Lifesaving Insulin Now (INSULIN) Act"; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; and issues related to HR 3576 "Inflation Reduction Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2022 · second_quarter · Q2
General issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; issues related to HR 5376 Build Back Better Act; and issues related to tax credits.
Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; general issues related to HR 5376 "Build Back Better Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6972 "Give Kids a Chance Act of 2022"; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to "Improving Needed Safeguards for Users for Lifesaving Insulin Now (INSULIN) Act"; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; and issues related to drug importation.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2022 · first_quarter · Q1
Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to funding for Pandemic influenza funding; issues related to RX to OTC switch; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; general issues related to HR 5376 "Build Back Better Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to COVID Vaccine Development; issues related to Clinical Trial Diversity; issues related to HR 19 "Lower Costs, More Cures Act of 2021; issues related to Accelerated Approval; issues related to HR 5416 "Give Kids a Chance Act"; issues related to HR 6972 "Give Kids a Chance Act of 2022"; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; and general issues related to Insulin pricing.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2021 · fourth_quarter · Q4
Issues related to tax reform; general issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to H.R. 3656 "Vaccine Access Improvement Act of 2021"; issues related to 163(n) interest limitation; issues related to Base Erosion and Anti-Abuse (BEAT) tax; issues related to Tax Credit; and issues related to S.3087 "Vaccine Access Improvement Act of 2021".
Issues related to S.912 "Protecting Seniors through Immunization Act; issues related to H.R. 2170 "HAPI Act"; issues related to H.R. 1978 "Protecting Seniors through Immunization Act"; and issues related to Medicare Negotiation in the Build Back Better Act.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2021 · third_quarter · Q3
Issues related to TRIPS Waiver.
Issues related to HR 3 "Lower Drug Costs Now Act of 2019"; issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to insulin pricing; issues related to funding for Pandemic influenza; issues related to Bipartisan Infrastructure Package; issues related to HR 550 "Immunization Infrastructure Modernization Act"; issues related to HR 3655 "Vaccine Injury Compensation Modernization Act"; issues related to RX to OTC switch; issues related to S.1132 "EPI Act"; issues related to HR 19 "Lower Costs, More Cures Act of 2021"; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Cures 2.0; issues related to Platform Technologies; issues related to Medicare Sequestration; issues related to Reconciliation; and issues related to Intellectual Property.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2021 · second_quarter · Q2
Issues related to Medicare sequestration.
Issues related to HR 3 "Lower Drug Costs Now Act of 2019"; issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; issues related to HR 1319 "American Rescue Plan"; general issues related to trade; general issues related to AMP CAP; general issues related to vaccines; issues related to 340B; issues related to insulin pricing; issues related to funding for Pandemic influenza; issues related to Flu Infrastructure Funding; issues related to HR 1978 "Protecting Seniors Through Immunization Act"; issues related to HR 2170 "Helping Adults Protect Immunity Act"; issues related to HR 550 "Immunization Infrastructure Modernization Act"; issues related to HR 2437 "Strengthening the Vaccines for Children Act of 2021"; issues related to HR 3655 "Vaccine Injury Compensation Modernization Act"; issues related to vaccine authorized for emergency use under HR 3705; issues related to RX to OTC switch; issues related to S.1132 "EPI Act"; issues related to S.2164 "Lower Costs, More Cures Act of 2021; and issues related to HR 19 "Lower Costs, More Cures Act of 2021".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2021 · first_quarter · Q1
Issues related to HR 3 "Lower Drug Costs Now Act of 2019"; issues related to drug pricing, issues related to COVID vaccine development; issues related to vaccine confidence; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; issues related to HR 1319 "American Rescue Plan"; general issues related to trade; general issues related to AMP CAP; general issues related to vaccines.
Issues related to 340B; issues related to Medicaid AMP CAP; issues related to Medicare sequestration.
Issues related to the R&D tax credit; issues related to Orphan Drug Tax Credit; general issues related to taxes.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · fourth_quarter · Q4
Issues related to Medicare Part D; issues related to IPI model; issues related to Medicaid AMPCAP; and issues related to Blended ASP Authorized Generics.
General issues related to supply chain.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to Executive Order on Flu Vaccines; issues related to HR3. "Lower Drug Cost Now act of 2019; general issues related to drug pricing; issues related to HHS Rebate Rule; issues related to insulin pricing; issues related to compulsory licensing; issues related to S.3548 "CARES Act"; and issues related to HR19 "Lower Costs, More Cures Act of 2019".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · third_quarter · Q3
Issues related to BARDA/Biodefense appropriations.
Issues related to foreign supply chain; and general issues related to supply chain.
Issues related to Buy America Executive Order.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · second_quarter · Q2
Issues related to BARDA/Biodefense appropriations; and issues related to S.4049 NDAA for FY 2021.
Issues related to Buy/America Executive Order and other general issues related to foreign supply chain.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; issues related to drug pricing; issues related to insulin pricing; issues related to CMMI insulin demo; issues related to copay accumulators; and Medicare administrative fees for vaccines and other general issues related to routine immunizations.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · first_quarter · Q1
Issues related to Foreign Supply Chain
Issues related to BARDA/Biodefense appropriations
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · fourth_quarter · Q4
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Issues related to Tax Reform; issues related to H.R. 1973 "Vaccine Access Improvement Act of 2019" and issues related to S. 1654 Vaccine Access
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · third_quarter · Q3
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S. 2082 "Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019".
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration;; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation; and issues related to H.R. 3 "Lower Drug Costs Now Act of 2019".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · second_quarter · Q2
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S. 1416 "Affordable Prescription for Patients Act of 2019".
Biodefense appropriation issues related to Biomedical Advanced Research and Development Authority (BARDA)
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · first_quarter · Q1
Issues related to tax reform.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation; issues related to S. 97 " Affordable and Safe Prescription Drug Importation Act"; issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to dietary supplements; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · fourth_quarter · Q4
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · third_quarter · Q3
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding;and Part D and other issues related to HR1892 "Bipartisan Budget Act of 2018.
Issues related to Border adjustability tax; issues related to H.R.4993; issues related to H.R.4993 "Vaccine Access Improvement Act of 2018"; and issues related to Orphan Drug Tax Credit
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · second_quarter · Q2
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to FDA User Fee Reauthorization; issues related to HR2212 "CREATES Act of 2017"; and issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017".
Issues related to the repeal and non-interference in Part D.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · first_quarter · Q1
Issues related to repealing IPAB in S.251 "Protecting Medicare from Executive Action Act of 2017"; and issues related to the repeal of Non-Interference in Medicare Part D.
Issues related to HR 4996 Vaccine Access Improvement Act of 2018
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing; and issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · fourth_quarter · Q4
Issues related to interest deductibility; issues related to stock attribution; issues related H.R. 1-Tax Cuts and Jobs Act; and issues related to foreign direct investment.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing;issues related to FDA approval of Follow-on Biologics; issues related to cosmetic regulations; issues related to insulin pricing; and issues related to Pandemic and All Hazards Preparedness (PAHPA).
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · third_quarter · Q3
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · second_quarter · Q2
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · first_quarter · Q1
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · fourth_quarter · Q4
Provisions of S.31 "Medicare Prescription Drug Price Negotiation Act; issues related to Medicare Part B reimbursement; and issues related to Medicare Part D program
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks; issues related to Center for Medicaid and Medicaid Services Innovation Center; Issues related to research and development innovation and education; general issues related to insulin pricing; general issues related to Tropical Disease PRV Program; general issues related to Vaccine Safety; issues related to Access to Adult Vaccines; issues related to H.R. 3299 Strengthening Public Health Emergency Response Act; importation issues related to S.122 Safe and Affordable Drugs from Canada Act of 2015; issues related to pricing and cost value; issues related to the Prescription Drug User Fee Act; and issues related to 21st Century Cures Initiative.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · third_quarter · Q3
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks;general issues related to the value of prescription medicines; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative; Issues related to research and development innovation and education; general issues related to emerging infectious diseases; general issues related to counterfeit pharmaceuticals; issues related to H.R. 3678 "Preserving Access to Orphan Drug Act of 2015"; general issues related to importation; general issues related to insulin pricing; general issues related to priority review vouchers; and general issues related to Tropical Disease PRV Program.
Provision: Division B-Zika response and preparedness under bill H.R. 3525 "Legislative Branch Appropriations Act, 2017".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · second_quarter · Q2
General issues related to corporate tax reform, including the deduction of interest; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Department of Treasury regulations on inversions.
General issues related to the importance of foreign direct investment in the U.S.
General issues related to the Medicare Part D Program and government price setting; and provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement and Center for Medicaid and Medicare Innovation Part B rule
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · first_quarter · Q1
Education and awareness of the 2015-2016 influenza season; all issues related to the Innovations for Healthier Americans Initiative; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Priority Review Vouchers; general issues related to Tropical Disease PRV Program; education and awareness of pandemic and biodefense funding; general issues related to the value of prescription medicines; issues related to S2742 "Promoting Biomedical Research and Public Health Patient Act" provision Section 6 National Vaccine Injury; issues related to S2512/H.R. "Adding Zika Virus to the FDA Priority Review Voucher Program Act"
General issues related to corporate tax reform, including the deduction of interest,general issues related to the 40% excise tax on employer-sponsored health care; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · fourth_quarter · Q4
Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · third_quarter · Q3
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; and general issues related to chronic care reform in the Medicare program.
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · second_quarter · 2A
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · second_quarter · Q2
General issues related to the 340B Federal Drug Pricing Program
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · first_quarter · Q1
Issues related to the Medicaid rebate policy; general issues related to the Medicare Part D program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to the Medicare Part B reimbursement of prescription drugs; proposals set forth in the President's Budget Request relating to applying a Medicaid rebate to Medicare Part D for low income subsidy beneficiaries, increasing the manufacturer Part D coverage gap discounts for brand name drugs, repealing the non-interference provision, restructuring generic and brand copayments for low income subsidy beneficiaries, and reducing reimbursement for Medicare Part B medicines; and all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"
Education and awareness of the 2014-2015 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; OTC-HSA; general issues related to awareness of Ebola; and education and awareness of cardiovascular disease and related treatments.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2014 · fourth_quarter · Q4
Issues related to the Medicaid drug rebate policy; issues related to Medicare Part B Reimbursement of prescription drugs; and general issues related to the Medicare Part D Program
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and coldmedicines that contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · first_quarter · Q1
S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · fourth_quarter · 4A
Issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; and raising awareness regarding illegal compounding of veterinary drugs for animals
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation ActReauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · third_quarter · 3A
S3239 and HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; and issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · second_quarter · 2A
Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; and general issues related to the USDA Wildlife Service Oral Rabies Vaccination Program.
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · fourth_quarter · Q4
Issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; and raising awareness regarding illegal compounding of veterinary drugs for animals
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · third_quarter · Q3
S3239 and HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; and issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · second_quarter · Q2
HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; general issues related to the USDA Wildlife Service Oral Rabies Vaccination Program.
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · first_quarter · Q1
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · fourth_quarter · Q4
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs including amendment No. 769 to H.R. 2112 "Consolidated and Further Continuing Appropriations Act, 2012"; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for C. Difficile; awareness about the company's Access to Medicines Program; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · third_quarter · Q3
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR2529 "Restoring Access to Medication Act", the Medication Therapy Management Program, and the Independent Payment Advisory Board (IPAB); awareness and issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S Res 243 "A resolution promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · second_quarter · Q2
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · first_quarter · Q1
General discussions regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)
Comparative effectiveness, including issues related to the Patient Centered Research Insitute, issues related to limitations on the use of Health Savings Accounts for over-the-counter medicines, repeal and defunding efforts, & general issues regarding implementation of HR3590 "The Patient Protection and Affordable Care Act" including the Medication Therapy Management Program transitions of care; awareness and issues related to patient access to diabetes care; awareness and issues related to patient access to atrial fibrillation care; all provisions of S668 "Health Care Bureaucrats Elimination Act" and HR452 "Medicare Decisions Accountability Act of 2011"; issues related to importation of prescription medicines; issues related to efforts to move pseudoephedrine products to prescription drug status; section 401 of S174 "Healthy Lifestyles and Prevention (HeLP) America Act"; and issues related to pandemic influenza and biodefense funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to VICP; and issues related to HR 3656 "Vaccine Access Improvement Act".
Issues related to S.150 "Affordable Prescriptions for Patients Act of 2023".
Issues related to Medicare Negotiations; and issues related to Drug Pricing Negotiations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to S.912 "Protecting Seniors through Immunization Act; and issues related to Medicare Negotiation.
General issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; issues related to HR 5376 Build Back Better Act; issues related to tax credits; and issues related to S.4417 "Patent Trial and Appeal Board Act of 2022".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to S.912 "Protecting Seniors through Immunization Act; issues related to Medicare Negotiation; and issues related to drug importation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to S.912 "Protecting Seniors through Immunization Act; issues related to Medicare Negotiation, issues related to Medicare Sequestration; and issues related to drug pricing.
General issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to H.R. 3656 "Vaccine Access Improvement Act of 2021"; issues related to S.3087 "Vaccine Access Improvement Act of 2021"; and issues related to HR 5376 Build Back Better Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to S.2428 "False Claims Act"; and issues related to Vaccine Injury Compensation Program.
Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to funding for Pandemic influenza; issues related to RX to OTC switch; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Platform Technologies; issues related to Medicare Sequestration; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; issues related to Intellectual Property; and issues related to Importation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to S.912 "Protecting Seniors through Immunization Act; issues related to H.R. 2170 "HAPI Act"; and issues related to H.R. 1978 "Protecting Seniors through Immunization Act".
Issues related to tax reform; general issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to H.R. 3656 "Vaccine Access Improvement Act of 2021"; issues related to 163(n) interest limitation; and issues related to Base Erosion and Anti-Abuse (BEAT) tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform; and general issues related to taxes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to BARDA/Biodefense appropriations.
Issues related to Buy America Executive Order.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to cosmetic regulations; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to OTC monograph reform; issues related to Executive Order on Flu Vaccines; issues related to CMMI Insulin demo; issues related to copay accumulators; and issues related to HR3. "Lower Drug Cost Now act of 2019".
Issues related to Medicare Part D; issues related to IPI model; and issues related to Medicaid AMPCAP.
Issues related to related to Tax impact on supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D; and issues related to home infusions of Part B medicines.
Issues related to Tax Reform; and issues related to Tax impact on supply chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Buy American Executive Order.
Issues related to Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to BARDA/Biodefense appropriations
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
Issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; issues related to international price index; and issues related to Medicare Part D.
Filing targets: Administration for Children & Families (ACF), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Issues related to S.340 "CREATES Act of 2019"; and issues related to HR 3199 "Terminating the Extension of Rights Misappropriated Act of 2019"
Issues related to S.99 "Medicare Drug Price Negotiation Act"; issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; and issues related to international price index.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Biodefence appropriation issues related to Biomedical Advanced Research and Development Authority (BARDA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to H.R.4993 "Vaccine Access Improvement Act of 2018"; and issues related to Orphan Drug Tax Credit
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding; and issues related to HR1892 "Bipartisan Budget Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding;and issues related to HR1892 "Bipartisan Budget Act of 2018.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Issues related to site expansions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to HR1625 "Consolidated Appropriations Act of 2018"; issues related to HR1892 "Bipartisan Budget Act of 2018"; issues related to National Institute of Health (NIH) funding; and issues related to Biomedical Advanced Research and Development Authority (BARDA)".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to site expansions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Issues related to Foreign Direct investment; and issues related to site expansions.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
General issues related to border adjustability tax; issues related to interest deductibility; issues related to Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the repeal of Non-Interference in Part D; general issues related to S.260 "Protecting Seniors' Access to Medicare Act of 2017".
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
All provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Corporate Tax Reform; and issues related to Department of Treasury regulations on inversions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
All provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Department of Treasury regulations on inversions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
General issues related to the importance of foreign direct investment in the U.S.
Education and awareness related to Atopic dermatitis awareness
General issues related to reforms to the Vaccine Injury Compensation Program (VICP).
General issues related to the Medicare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement; general issues related to Medicare Chronic Care Reform
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
Issues related to the Medicaid prescription drug rebate program policy; general issues related to the Medicare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; issues related to the Over The Counter (OTC) Monograph reform; general issues related to access to adult vaccines; and all provisions of S1972 "Airline Access to Emergency Epinephrine Act of 2015.".
Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
General issues related to the 340B Federal Drug Pricing Program
Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.
Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Corporate tax reform; a strengthened and permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act"
General issues related to the 340B Federal Drug Pricing Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions
Reauthorization of the Prescription Drug User Fee Act (PDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to provider reimbursement for the administration of vaccines; issues related to changing reimbursement for physicians under the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General discussions regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Punitive damages provisions in HR5 "Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act; and general issues related to efforts to reform the Vaccine Injury Compensation Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE